September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
PROGNOSTIC VALUE OF THE TOMOGRAPHIC PHENOTYPIC CHARACTERIZATION OF MYOPIC CHOROIDAL NEOVASCULARIZATION.
Author Affiliations & Notes
  • Isabel Pascual-Camps
    Department of Ophthalmology, Universitary and Polytechnich Hospital La Fe, Valencia, Valencia, Spain
  • Pablo Hernández-Martínez
    Department of Ophthalmology, Universitary and Polytechnich Hospital La Fe, Valencia, Valencia, Spain
  • LAURA MONJE-FERNANDEZ
    Ophthalmology Department, Universitary Assistential Complex of León, León, Spain
  • María Andreu-Fenoll
    Department of Ophthalmology, Universitary and Polytechnich Hospital La Fe, Valencia, Valencia, Spain
  • Rosa Dolz-Marco
    Department of Ophthalmology, Universitary and Polytechnich Hospital La Fe, Valencia, Valencia, Spain
  • Roberto Gallego-Pinazo
    Department of Ophthalmology, Universitary and Polytechnich Hospital La Fe, Valencia, Valencia, Spain
  • Footnotes
    Commercial Relationships   Isabel Pascual-Camps, None; Pablo Hernández-Martínez, None; LAURA MONJE-FERNANDEZ, None; María Andreu-Fenoll, None; Rosa Dolz-Marco, None; Roberto Gallego-Pinazo, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2131. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Isabel Pascual-Camps, Pablo Hernández-Martínez, LAURA MONJE-FERNANDEZ, María Andreu-Fenoll, Rosa Dolz-Marco, Roberto Gallego-Pinazo; PROGNOSTIC VALUE OF THE TOMOGRAPHIC PHENOTYPIC CHARACTERIZATION OF MYOPIC CHOROIDAL NEOVASCULARIZATION.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2131.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyze different tomographic characteristics and their influence in visual prognosis and need of treatment in patients with myopic choroidal neovascularization (CNV).

Methods : We conducted a retrospective, observational study including all newly diagnosed patients with myopic CNV from May 2013 to May 2015, receiving antiangiogenic therapy with intravitreal ranibizumab injections in a pro re nata regime. Demographic data and visual acuity (VA) were collected. Optical coherence tomography (OCT) scans were evaluated analyzing the presence, or absence of a hyperreflective envelope around the neovascular tissue. Statistical analysis was performed with non-parametric test (Kruskal Wallis).

Results : Twenty-seven eyes of 27 patients (mean age: 67,66 years +/- 11,42; 6 men: 21 women) were included. Sixteen patients were classified as group 1 (presence of hypereflective envelope; mean age: 68,27 years +/- 11,26; 5 men: 11 women); 5 patients were classified as group 2 (absence of the envelope; mean age: 69,25 years +/- 13,00; 5 women); 6 patients were classified as group 3 (mixed lesion; mean age: 64,72 years +/- 12,21; 1 man: 21 women). Mean baseline VA in logMAR was 0,82 (SD 0,95; 0,0-3,0) and final VA 0,42 (SD 0,43; 0,0-1,3); mean follow-up time was 10,66 months (SD 6,37; 0,0-27,37). No statistically significant differences were found between the 3 groups regarding the age (p=0.543), follow-up time (p=0.053), baseline VA (p=0,578), final VA (p=0,267), macular choroidal volume (p=0,904) and central choroidal thickness (p=0,883). Differences were observed in the total number of injections (p=0,01; Group 1: 1,8+/-1,1; Group 2: 2,69+/-1,14; Group 3: 3,33 +/-1,03). A statistically significant improvement between baseline and final VA was found only in Group 1 (p=0,006).

Conclusions : We suggest a new anatomic tomographic classification in patients with myopic CNV based on the presence or absence of the hyperreflective envelope around the neovascular tissue. The presence of this sheath was related with a better visual prognosis with less number of intravitreal injections. Further studies are warranted in order to confirm these results.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×